Diligence memo · auto-generated · as of July 2, 2026
Aspire BioPharma, Inc.
Aspire BioPharma, Inc. looks over-valued against its niche peers and is at-risk on financing cadence.
Businessfiled
Aspire BioPharma, Inc. operates in Pharmaceuticals, based in HUMACAO.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Aspire BioPharma, Inc. has raised $10M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $10M on 2023-11-01.
Most recent recorded round closed around 2023-11-01.
Valuation (modeled)modeled
Provath models Aspire BioPharma, Inc. at approximately $69M (range $11M–$175M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 2.13× the median modeled value of Series A Pharmaceuticals companies in 2022–2024 (64 peers) — value vs value, same stage and era. Issuer reports no revenue, yet is modeled well above niche peers.
Financing rhythm & timingmixed
Last raise 2.7 yr ago; this sector typically re-raises about every 13 months.
Past due for a raise versus sector cadence — watch for distress or a bridge.
Comparablesmixed
Capital scale ranks ahead of 54% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 49% of those peers.
Closest niche peers: Hallux, Inc., Enalare Therapeutics Inc., Silver Creek Pharmaceuticals, Inc., NQ PE Project Stingray Parent, L.P., Acta Pharmaceuticals, Inc..
Peoplefiled
5 named people on file across officers, directors and signatories.
Risks & flagsmixed
Overdue for a raise versus sector norm — distress or bridge risk.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.